Diving Deeper into MyDx

Home / MyDx Company Announcements / Diving Deeper into MyDx

We want to know more about YOU and for you to know everything about us!

MyDx is a science, technology, and innovation company based in San Diego, California. We created the first ever battery-operated, handheld, electronic cannabis analyzer for consumers, allowing people to take control of what they are putting into their bodies and making sure they are armed with as much information as possible. MyDx uses nanotechnology to measure chemical profiles and we are constantly working to create new sensors and technology for you.

The MyDx Mission: “To empower people to live a healthier life by revealing the chemicals in what they eat, drink and inhale.”

At MyDx, we believe that clear and accurate information empowers both progress and you as a consumer.

MyDx is traded on the OTCQB under the ticker symbol MYDX.

According to OTC Markets, “The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their reporting, have a minimum bid price of $0.01, may not be in bankruptcy and must undergo an annual verification and management certification process. These standards provide a strong baseline of transparency to improve the information and trading experience for investors.”

OTC Markets Group also hosts the OTCQX® Best Market, which is for more established, investor-focused companies.

This means you cannot buy MyDx stock directly from us at MyDx, but you are able to purchase stock through a licensed stockbroker or by registering online and using an online trading account.

MyDx is independently audited and uses a company called Sadler, Gibb & Associates LLC. You are welcome to view our annual reports and SEC filings here.

In April 2018, MyDx welcomed Dr. Heiner Dreismann the former CEO of Roche Molecular Systems as the new Chairman of the Executive Advisory Board. While serving as CEO at Roche, Roche became the global leader in molecular diagnostics by a significant expansion of their portfolio of molecular tests and respective instrumentation.

MyDx CEO Daniel Yazbeck said, “Dr. Dreismann is a top industry expert in the field of molecular and medical diagnostics.  He has a proven track record of leadership in the development, commercialization, and adoption of diagnostics, and brings valuable real-world experience as we continue to develop our advance our smart devices and data monetization strategies in 2018.”  

As you can see, it is imperative to us at MyDx to continue to innovate and create the best science and technology has to offer, both for industry insiders and companies and to you as a consumer.

We are looking to the future to create more and more devices to keep you safe, healthy, and informed.

Keep an eye on us as we move forward! Big things are coming!


Related Posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.